Having a beer!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You still holding here? They've been putting out news regularly here. Maybe we can get a boost soon..
We've cleaned up .03s. I would say we set a new base around .05. May be a few flippers left. I'm going to shoot the company an email over the weekend.
Yes, I'm waiting on the updates here. This one could really make us a lot of money from down here. I just kind of quit watching the ticks here. There can't be more than a 5-7 million float currently. Could get very exciting soon.
May not be nothing. I was just curious. I haven't seen that mm much. Here is some info on the company. Maybe a more experience trader can answer that question.
https://www.celadonfinancial.com/about/about-us/
Founded in 1986, Celadon Financial Group is a full service broker-dealer serving financial institutions, hedge funds, money managers, and high net-worth clients in the U.S. and abroad. Drawing on our extensive experience across multiple facets of the securities industry, we provide professional traders and individual investors with advanced trading tools and the personal support they need to develop effective trading strategies. From skillful order execution to actionable trading strategies, we consistently work to enhance value for our clients.
Strong relationships
At Celadon, our long-term client relationships are our most valuable assets. That’s why we put in the time and effort to understand your investment objectives – from your day to day trading style to your long-term vision and goals. By listening closely to your needs, we’re able to make more informed recommendations on how you can keep pace with changing market conditions and business priorities. Our familiarity with your trading requirements combined with our operational prowess means we can support your business now, and for many years to come.
Multiple custodians enable global trading and clearance of equities, options, fixed income, ETFs, and commodity futures.
RBC Capital Markets, LLC.
Wedbush Securities Inc.
INTL FCStone Inc.
Celadon offers a comprehensive range of products and services at competitive rates.
Direct market access platforms with full connectivity to major U.S. and international market centers.
Sterling Trader Pro
RediPlus
Prime brokerage
Agency desk
Portfolio margin
Securities lending
Online account access
Portfolio reporting and analytics
Soft Dollars
Founded in 1986, Celadon Financial Group is a full service broker-dealer serving financial institutions, hedge funds, money managers, and high net-worth clients in the U.S. and abroad. Drawing on our extensive experience across multiple facets of the securities industry, we provide professional traders and individual investors with advanced trading tools and the personal support they need to develop effective trading strategies. From skillful order execution to actionable trading strategies, we consistently work to enhance value for our clients.
Strong relationships
At Celadon, our long-term client relationships are our most valuable assets. That’s why we put in the time and effort to understand your investment objectives – from your day to day trading style to your long-term vision and goals. By listening closely to your needs, we’re able to make more informed recommendations on how you can keep pace with changing market conditions and business priorities. Our familiarity with your trading requirements combined with our operational prowess means we can support your business now, and for many years to come.
Multiple custodians enable global trading and clearance of equities, options, fixed income, ETFs, and commodity futures.
RBC Capital Markets, LLC.
Wedbush Securities Inc.
INTL FCStone Inc.
Celadon offers a comprehensive range of products and services at competitive rates.
Direct market access platforms with full connectivity to major U.S. and international market centers.
Sterling Trader Pro
RediPlus
Prime brokerage
Agency desk
Portfolio margin
Securities lending
Online account access
Portfolio reporting and analytics
Soft Dollars
How long has SPLN been on the L2? Typically don't see that MM much.
$GTHR- covid-19 testing and tracking, moving back up! Slow steady climb back to 52 week high soon.
This one is ready to run. I wonder if someone knows something? These has steadily moved up on low volume. When larger shareholders start adding there won't be any large blocks left.
$GTHR- you guys watching this one? These guys create testing for zootonic diseases. They utilize RT-PCR and F-PCR. Has steadily moved up since they went current. Government funding may be in play here.
Agreed. I really think these guys were on to something before they got screwed by that private investor. Now would be a great time to get back on track and land a big government grant.
Can't wait for us to get some updates. Shares are gone here at these levels. Let's see some testing news drop. I wonder if they have moved into there newest facility yet?
Share update, NVSOS update, filings are next imo.
RSCZF--- more news today! Company is really putting on a show.
https://finance.yahoo.com/news/high-standard-health-care-becomes-110010043.html
VANCOUVER, British Columbia, July 08, 2020 (GLOBE NEWSWIRE) -- Global Care Capital Inc. (CSE:HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company High Standard Health Care Ltd. (“High Standard Health Care”) has, pursuant to entering into an Approved Vendor Contract on July 6th, 2020, become an Approved Vendor for Nevada based long term care facility, Alta Skilled Nursing and Rehab Centre (“Alta”) https://www.altanursingandrehab.com/.
High Standard Health Care specializes in procuring personal protective equipment (“PPE”) including but not limited to respiratory masks, hand sanitizer, gowns, infrared thermometers and face shields and has been active in procurement during COVID-19 for hospitals, municipalities, long-term care facilities, fire departments and police departments.
High Standard Health Care has existing relationships with China based manufacturers who supply PPE products. High Standard Health Care provides production orders to these manufacturers from time to time at which point the manufacturers will allocate production from their facilities to support these orders.
Approved Vendor Contract
Under the terms of the contract, Alta will engage High Standard Health Care as an Approved Vendor for future procurement of PPE. Alta will contact High Standard Health Care to discuss PPE needs, specifications, quantities, delivery dates and pricing (“Purchase Order Details”). High Standard Health Care will provide Alta with a quote with the purchase order details. Alta will notify High Standard Health Care within two business days after receiving the quote whether to proceed with a purchase order. High Standard Health Care will then complete the order and deliver the PPE to Alta in accordance with the purchase order. Once Alta receives the PPE in good order, High Standard Health Care will invoice Alta for payment.
Look how then this got once we bought .03s and .04s. This one will easily smash into the teens with news. So fortunate to be in down here before the fomo.
RSCZF---. Big news $17.25 million LOI for Covid-19 test kits to the Chilean market! This one is going to explode one day soon imo.
https://www.otcmarkets.com/stock/RSCZF/news/story?e&id=1638731
ViraxClear Receives ISP Approval for ViraxClear Rapid Test Kit Distribution to Chile With Signed LOI for up to 3 million Test Kits
VANCOUVER, British Columbia, July 07, 2020 (GLOBE NEWSWIRE) -- Global Care Capital Inc. (CSE: HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company, ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd. (“SBD”) has received approval on July 3rd, 2020 from El Instituto de Salud Pública de Chile (“ISP”) for the distribution of COVID-19 Rapid Antibody Test Kits (“Test Kits”) supplied by its previously disclosed manufacturing partners, Innovita Biological Technology Co., Ltd and Vazyme Biotech Co., Ltd (“Innovita”, “Vazyme”), for the Chilean market. ViraxClear has signed a non-binding LOI with Biosonda Biotecnologia (“Biosonda”) for the distribution of up to 3 million Test Kits for the Chilean market, a contract valued at up to $17.25 million in gross revenue.
Figure 1
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f21c6f66-8b2f-4b6c-a13d-fd8e9822d37b
Distribution Contract for Test Kits in Chile
ViraxClear has received initial orders for trials and market testing of their Test Kits for the Chilean market and manufacturing is expected to commence over the next 60 days. The LOI provides for a 60-day exclusivity period during which ViraxClear and Biosonda intend to sign a definitive agreement with a total contract value of up to $17.25 million.
Biosonda is a biotechnology company founded in Chile in 1992 by leading scientists. It is currently one of the main distribution companies of products for scientific research and clinical diagnosis in Chile, with a recognizable corporate image in the national market. Biosonda works with some of the top global brands in the clinical and diagnostic industries and handle everything from marketing, import, logistics, research and development and sales.
The Biosonda commercial department is made up of a sales force, with a high degree of specialization and extensive experience in the market made up of experts in molecular biology and immunology. They offer a technical service laboratory for equipment maintenance, repair and training, a personalized after-sales service, and a commercial-logistics team that manages the tasks of quotation, import, logistics, inventory, orders and dispatch to provide an optimum service.
Alex Somjen, CEO of Global Care Capital Inc., stated, “This distribution deal represents the culmination of months of negotiating by ViraxClear with top distributors in key global regions. Biosonda is in a perfect position to roll out mass testing for the region with Chile already seeing 288,000 confirmed cases of COVID-19 and the population requiring Antibody Testing once the curve has flattened.”
ISP Approval
The Chilean government require medical testing devices to receive ISP Approval before they can be sold in Chile. Both Innovita and Vazyme, ViraxClear suppliers, are now on the list of ISP Approved factories, allowing ViraxClear tests to be imported and sold nationally.
Established in 2006, Innovita is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. The CE and NMPA (formerly known as CFDA) approved Innovita serology tests have performed particularly well during preliminary clinical tests carried out by the COVID-19 Testing Project; a multidisciplinary team of researchers and physicians at UCSF, UC Berkeley, Chan Zuckerberg Biohub and Innovative Genetics Institute. According to their studies, Innovita tests scored a 96.3 % specificity (NPV); 83.3% Sensitivity (PPV) with an IN-HOUSE ELISA test (gold reference standard) giving 99.1 % specificity (NPV); 81.8 % Sensitivity (PPV): https://covidtestingproject.org/
Vazyme, which is a highly reputable producer of enzymes and antibodies with products covering clinical diagnosis, molecular diagnostics, high-throughput sequencing and life science research, as well as RNA sequencing, enabling customers and reagent manufacturers to get enzymes with higher resistance. Vazyme owns a dedicated 8000 m2 R&D site and have established the Biotechnology Industry Research Institute, which is comprised of a team of nearly 100 scientists.
The Test Kits are intended for the qualitative detection of IgG and IgM antibodies against 2019 Novel Coronavirus, produced by the immune system after virus infection. IgM is the earliest antibody that appears upon the first immune response, with detection indicating an early stage infection. IgG is produced later and lasts a long time in the body, indicating a prior infection. The combination of the two markers offers an insight into what stage the virus has reached.
About ViraxClear
ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.
http://www.viraxclear.com
info@viraxclear.com
About Global Care
Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.
http://www.globalcarecapital.com
GLOBAL CARE CAPITAL INC.:
Company Contact:
Alex Somjen, President & CEO
asomjen@globalcarecapital.com
RSCZF--- Check this one out. Shares should be worth a lot more.
https://globalcarecapital.com/news/
When news hits that they have developed a covid test or some way to track zootonic diseases there will be no stopping this one. There are no shares at this level. There shouldn't be any big blocks to chew through only blue skies when this hits. The test they do is the F-PCR test and they also have the capability of doing RT-PCR test. This is going to awesome here.
RSCZF---. Volume coming in here guys. Big news $17.25 million LOI for Covid-19 test kits to the Chilean market!
https://stockhouse.com/news/press-releases/2020/07/07/viraxclear-receives-isp-approval-for-viraxclear-rapid-test-kit-distribution-to
RSCZF---. Big news $17.25 million LOI for Covid-19 test kits to the Chilean market! This one is going to explode one day soon imo.
https://www.otcmarkets.com/stock/RSCZF/news/story?e&id=1638731
ViraxClear Receives ISP Approval for ViraxClear Rapid Test Kit Distribution to Chile With Signed LOI for up to 3 million Test Kits
VANCOUVER, British Columbia, July 07, 2020 (GLOBE NEWSWIRE) -- Global Care Capital Inc. (CSE: HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company, ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd. (“SBD”) has received approval on July 3rd, 2020 from El Instituto de Salud Pública de Chile (“ISP”) for the distribution of COVID-19 Rapid Antibody Test Kits (“Test Kits”) supplied by its previously disclosed manufacturing partners, Innovita Biological Technology Co., Ltd and Vazyme Biotech Co., Ltd (“Innovita”, “Vazyme”), for the Chilean market. ViraxClear has signed a non-binding LOI with Biosonda Biotecnologia (“Biosonda”) for the distribution of up to 3 million Test Kits for the Chilean market, a contract valued at up to $17.25 million in gross revenue.
Figure 1
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f21c6f66-8b2f-4b6c-a13d-fd8e9822d37b
Distribution Contract for Test Kits in Chile
ViraxClear has received initial orders for trials and market testing of their Test Kits for the Chilean market and manufacturing is expected to commence over the next 60 days. The LOI provides for a 60-day exclusivity period during which ViraxClear and Biosonda intend to sign a definitive agreement with a total contract value of up to $17.25 million.
Biosonda is a biotechnology company founded in Chile in 1992 by leading scientists. It is currently one of the main distribution companies of products for scientific research and clinical diagnosis in Chile, with a recognizable corporate image in the national market. Biosonda works with some of the top global brands in the clinical and diagnostic industries and handle everything from marketing, import, logistics, research and development and sales.
The Biosonda commercial department is made up of a sales force, with a high degree of specialization and extensive experience in the market made up of experts in molecular biology and immunology. They offer a technical service laboratory for equipment maintenance, repair and training, a personalized after-sales service, and a commercial-logistics team that manages the tasks of quotation, import, logistics, inventory, orders and dispatch to provide an optimum service.
Alex Somjen, CEO of Global Care Capital Inc., stated, “This distribution deal represents the culmination of months of negotiating by ViraxClear with top distributors in key global regions. Biosonda is in a perfect position to roll out mass testing for the region with Chile already seeing 288,000 confirmed cases of COVID-19 and the population requiring Antibody Testing once the curve has flattened.”
ISP Approval
The Chilean government require medical testing devices to receive ISP Approval before they can be sold in Chile. Both Innovita and Vazyme, ViraxClear suppliers, are now on the list of ISP Approved factories, allowing ViraxClear tests to be imported and sold nationally.
Established in 2006, Innovita is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. The CE and NMPA (formerly known as CFDA) approved Innovita serology tests have performed particularly well during preliminary clinical tests carried out by the COVID-19 Testing Project; a multidisciplinary team of researchers and physicians at UCSF, UC Berkeley, Chan Zuckerberg Biohub and Innovative Genetics Institute. According to their studies, Innovita tests scored a 96.3 % specificity (NPV); 83.3% Sensitivity (PPV) with an IN-HOUSE ELISA test (gold reference standard) giving 99.1 % specificity (NPV); 81.8 % Sensitivity (PPV): https://covidtestingproject.org/
Vazyme, which is a highly reputable producer of enzymes and antibodies with products covering clinical diagnosis, molecular diagnostics, high-throughput sequencing and life science research, as well as RNA sequencing, enabling customers and reagent manufacturers to get enzymes with higher resistance. Vazyme owns a dedicated 8000 m2 R&D site and have established the Biotechnology Industry Research Institute, which is comprised of a team of nearly 100 scientists.
The Test Kits are intended for the qualitative detection of IgG and IgM antibodies against 2019 Novel Coronavirus, produced by the immune system after virus infection. IgM is the earliest antibody that appears upon the first immune response, with detection indicating an early stage infection. IgG is produced later and lasts a long time in the body, indicating a prior infection. The combination of the two markers offers an insight into what stage the virus has reached.
About ViraxClear
ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.
http://www.viraxclear.com
info@viraxclear.com
About Global Care
Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.
http://www.globalcarecapital.com
GLOBAL CARE CAPITAL INC.:
Company Contact:
Alex Somjen, President & CEO
asomjen@globalcarecapital.com
RSCZF---. Big news $17.25 million LOI for Covid-19 test kits to the Chilean market!
https://www.otcmarkets.com/stock/RSCZF/news/story?e&id=1638731
ViraxClear Receives ISP Approval for ViraxClear Rapid Test Kit Distribution to Chile With Signed LOI for up to 3 million Test Kits
VANCOUVER, British Columbia, July 07, 2020 (GLOBE NEWSWIRE) -- Global Care Capital Inc. (CSE: HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company, ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd. (“SBD”) has received approval on July 3rd, 2020 from El Instituto de Salud Pública de Chile (“ISP”) for the distribution of COVID-19 Rapid Antibody Test Kits (“Test Kits”) supplied by its previously disclosed manufacturing partners, Innovita Biological Technology Co., Ltd and Vazyme Biotech Co., Ltd (“Innovita”, “Vazyme”), for the Chilean market. ViraxClear has signed a non-binding LOI with Biosonda Biotecnologia (“Biosonda”) for the distribution of up to 3 million Test Kits for the Chilean market, a contract valued at up to $17.25 million in gross revenue.
Figure 1
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f21c6f66-8b2f-4b6c-a13d-fd8e9822d37b
Distribution Contract for Test Kits in Chile
ViraxClear has received initial orders for trials and market testing of their Test Kits for the Chilean market and manufacturing is expected to commence over the next 60 days. The LOI provides for a 60-day exclusivity period during which ViraxClear and Biosonda intend to sign a definitive agreement with a total contract value of up to $17.25 million.
Biosonda is a biotechnology company founded in Chile in 1992 by leading scientists. It is currently one of the main distribution companies of products for scientific research and clinical diagnosis in Chile, with a recognizable corporate image in the national market. Biosonda works with some of the top global brands in the clinical and diagnostic industries and handle everything from marketing, import, logistics, research and development and sales.
The Biosonda commercial department is made up of a sales force, with a high degree of specialization and extensive experience in the market made up of experts in molecular biology and immunology. They offer a technical service laboratory for equipment maintenance, repair and training, a personalized after-sales service, and a commercial-logistics team that manages the tasks of quotation, import, logistics, inventory, orders and dispatch to provide an optimum service.
Alex Somjen, CEO of Global Care Capital Inc., stated, “This distribution deal represents the culmination of months of negotiating by ViraxClear with top distributors in key global regions. Biosonda is in a perfect position to roll out mass testing for the region with Chile already seeing 288,000 confirmed cases of COVID-19 and the population requiring Antibody Testing once the curve has flattened.”
ISP Approval
The Chilean government require medical testing devices to receive ISP Approval before they can be sold in Chile. Both Innovita and Vazyme, ViraxClear suppliers, are now on the list of ISP Approved factories, allowing ViraxClear tests to be imported and sold nationally.
Established in 2006, Innovita is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. The CE and NMPA (formerly known as CFDA) approved Innovita serology tests have performed particularly well during preliminary clinical tests carried out by the COVID-19 Testing Project; a multidisciplinary team of researchers and physicians at UCSF, UC Berkeley, Chan Zuckerberg Biohub and Innovative Genetics Institute. According to their studies, Innovita tests scored a 96.3 % specificity (NPV); 83.3% Sensitivity (PPV) with an IN-HOUSE ELISA test (gold reference standard) giving 99.1 % specificity (NPV); 81.8 % Sensitivity (PPV): https://covidtestingproject.org/
Vazyme, which is a highly reputable producer of enzymes and antibodies with products covering clinical diagnosis, molecular diagnostics, high-throughput sequencing and life science research, as well as RNA sequencing, enabling customers and reagent manufacturers to get enzymes with higher resistance. Vazyme owns a dedicated 8000 m2 R&D site and have established the Biotechnology Industry Research Institute, which is comprised of a team of nearly 100 scientists.
The Test Kits are intended for the qualitative detection of IgG and IgM antibodies against 2019 Novel Coronavirus, produced by the immune system after virus infection. IgM is the earliest antibody that appears upon the first immune response, with detection indicating an early stage infection. IgG is produced later and lasts a long time in the body, indicating a prior infection. The combination of the two markers offers an insight into what stage the virus has reached.
About ViraxClear
ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.
http://www.viraxclear.com
info@viraxclear.com
About Global Care
Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.
http://www.globalcarecapital.com
GLOBAL CARE CAPITAL INC.:
Company Contact:
Alex Somjen, President & CEO
asomjen@globalcarecapital.com
The only problem I have currently is everything your saying is your opinion. The things your are saying is not facts. You're making assumptions and I'm not biased enough to say that you are right or wrong but you don't know yet.... You're assuming and that can be dangerous if this one does take off.
Man look at VXR#. They had lots of dillution and look where they are. Let's see what the FDA says before we jump to conclusions. This drug is definitely a different drug from Regen! Plus we are not supplying the bad covid patients. They are looking at moderate covid patients.
Thank you Reiko, I couldn't have put it better. This should move back up in a stair stepping way. Ready for Monday and next week.
Major, I'm loving this right here. I've seen this set up 4 different times this year already. We going up on phase 3 news.
I feel pretty good about my investment here. I'll be honest that I didn't like the way it traded yesterday but I was able to more than double my position. This gapped up to .50 and for the most part it is profit takers. This will move back up next week imo. There is no bad news and once the paperwork for phase 3 trials are filed I fully expect this one to do just like every other Bio stock in trials, GO UP!
What a run this has been here. I think my first buy was around .07.
No one knows anything about the company but what we read online. There is always a big possibility that the company will go public and flop on the shareholders. There are companies that do it the right way and grow. If you listen to traders that have the same info we do, that have a biased opinion they are here for one reason and one reason only....
Dress, it looks like the drug failed because of the adverse side effects in 80% of patients. Brother we didn't get to skip Phase 2 for no reason at all. Anyone selling because of another companies bad news could miss out. There isn't many companies in the Phase 3 trials. I think we are still okay here.
https://www.clinicaltrialsarena.com/news/kevzara-us-covid19-trial-data/
$RSCZF Covid-19 big time stock. Covid tests, ventilators, N95 mask, etc. This stock has it all. Just signed a big big contract in the Philippines.
https://mobile.twitter.com/viraxclear
https://viraxclear.com/#
https://www.otcmarkets.com/stock/RSCZF/news/story?e&id=1631771
ViraxClear Receives PFDA Approval for ViraxClear Rapid Test Kit Distribution to the Philippines
VANCOUVER, British Columbia, June 25, 2020 (GLOBE NEWSWIRE) -- Global Care Capital Inc. (CSE: HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company, ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd. has, further to the press release dated May 19th, 2020, received its approval certificate from the Philippines Food And Drug Administration (“PFDA”) for the distribution of COVID-19 Rapid Antibody Test Kits (“Test Kits”) for the Philippines market with a contract valued at up to $7.5 million in gross sales for the distribution of up to 1 million Test Kits for the Philippines.
COVID-19 Rapid Antibody Test Kits
https://www.globenewswire.com/NewsRoom/AttachmentNg/3348b7d1-3659-4a41-a664-b0b7e3942dc1
Distribution Contract for Test Kits in the Philippines
Following PFDA approval, Philippines medical device distribution company Novarad Asia Pacific Company (“Novarad”) has become ViraxClear’s exclusive distribution partner for the Philippines for ViraxClear Test Kits. The full contract value is worth up to $7.5 million, over a period of 1 year.
Alex Somjen, CEO of Global Care, stated “This distribution deal represents the first of many similar deals that ViraxClear is currently lining up with other strategic distribution partnerships it has been working on over the last few months. The Philippines is a major economy in South East Asia and we are excited to work with Novarad, who are very well positioned to market the ViraxClear products to its’ 100 million + population.”
PFDA Approval
The PFDA requires test kits to be on their approved list before being allowed through customs for sale in the country. ViraxClear tests have been approved in collaboration with Hangzhou Clongene Biotech Ltd., the ViraxClear manufacturing partner for the Philippines region.
Hangzhou Clongene Biotech Ltd. (“Clongene”) is a high-tech enterprise specialized in biological raw materials and in vitro diagnostic products. Founded in 2004, Clongene is equipped with state-of-the-art ISO 13485:2016 accredited- China GMP compliant R&D and manufacturing facilities covering 19,000 square meters in Hangzhou, China. Their products have obtained CE certificates, FSC certificates and US FDA 510(k) Clearances. Their product lines include Raw materials, Antibodies, Antigens, Enzymes, Immuno diagnosis, Fluorescence immunoassay (FIA) and Molecular diagnosis- PCR.
About ViraxClear
ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.
http://www.viraxclear.com
info@viraxclear.com
About Global Care
Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.
GLOBAL CARE CAPITAL INC.:
Company Contact:
Alex Somjen, President & CEO
asomjen@globalcarecapital.com
https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
Clinical Research Phase Studies
Phase 1
?
Study Participants: 20 to 100 healthy volunteers or people with the disease/condition.
Length of Study: Several months
Purpose: Safety and dosage
Approximately 70% of drugs move to the next phase
Phase 2
?
Study Participants: Up to several hundred people with the disease/condition.
Length of Study: Several months to 2 years
Purpose: Efficacy and side effects
Approximately 33% of drugs move to the next phase
Phase 3
?
Study Participants: 300 to 3,000 volunteers who have the disease or condition
Length of Study: 1 to 4 years
Purpose: Efficacy and monitoring of adverse reactions
Approximately 25-30% of drugs move to the next phase
Phase 4
?
Study Participants: Several thousand volunteers who have the disease/condition
Purpose: Safety and efficacy
How many companies get a recommendation to skip phase trial 2 and go into phase trial 3. There must have been some pretty good results from phase 1. Dollars coming here soon imo.
https://www.proactiveinvestors.co.uk/companies/news/923054/revive-therapeutics-initiation-report-923054.html
Hell a million in volume last time put us over .11 briefly. Just think what real news would do. If these guys stay away from toxic debt this stock is going to make a big move in PPS. One of the last filing said they had cancelled shares so that was like 7 million back in the treasury. Building a 5.6 million dollar facility is very telling to for what's coming imo. I'm wondering when news is coming??? No reason to hold back now that they are current with their filings.
Mardah, maybe I'm (we) are crazy but when this decides to run again like before I wouldn't want to be without shares. I got those .03s for a while now and will add on any dips. This should be over .10 on just basics. Wait until they land a govt contract, this will go freaking ballistic imo. The world changed when covid19 happened and this guys will be able to predict, find, and track any zootonic disease. How huge could this one be in a year, months, hell even weeks.
Adding here. Probably means merger close to being finalized maybe. Exchange of shell.
Crazy thing is people are selling down here and we know they are killing is behind the scenes. Didn't even wait until filings or their game plan was revealed. We need to thank Me. Miller where ever he is. Lol.
Impatient flippers. Another one at .03. going to try and free up some funds here if it is still available.
Finally was able to catch some shares below .30.
You are correct friend. I believe insiders took a large chunk when filings hit back in March. Reading between the lines of the last email it looks they may try to avoid convertibles if possible. Something is going down here because you don't have plans to build a 5.6 million dollar building without significant resources or backings. This has government funding written all over it imo.
I can't figure out why people aren't catching on here. The shares are going to worth a lot more in the coming months.
Sorry Adam, been working hard today. To answer your question, I'm not a mod. I just want to know when make our run to $5?!
Bid is tightening up here. Could see a jump soon.